Prostate CancerPROSPEXNCT07096596
Prostate Cancer Study of Patient Experiences
An observational study of Prostate Cancer, run by Ankara University at 1 site in Turkey (Türkiye).
Trial summary
The PROSPEX (PROstate cancer Study of Patient EXperiences) survey is designed to systematically assess the lived experiences, challenges, and unmet needs of individuals diagnosed with prostate cancer. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostate Cancer
- How many people
- 3,000 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- Aug 2025to Dec 2025
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: The study population will consist of adult individuals (aged 18 and above) who have been diagnosed with prostate cancer, regardless of disease stage or treatment status. Participants will be recruited internationally and will represent a diverse range of backgrounds, healthcare settings, and geographic regions. The study aims to include patients with varying experiences, including those currently undergoing treatment, those in remission, and those living with advanced or recurrent disease. All participants must be able to provide informed consent and complete the online survey.
Who may be able to join
- Adults (aged 18 years or older). Diagnosed with prostate cancer at any stage (localized, locally advanced, metastatic, or recurrent).
- Able to understand and provide informed consent for participation. Willing and able to complete the online survey in the available languages. Access to the internet and a device to complete the survey.
Who cannot join
- Individuals who have not been diagnosed with prostate cancer. Individuals under 18 years of age. Inability to provide informed consent. Inability to complete the survey due to cognitive, language, or technical barriers.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Ankara University Faculty of Medicine
Ankara, Ankara, 06590
Yüksel Ürün, M.D., +905304517798, yukselurun@gmail.com
Satı Coşkun Yazgan, M.D., +903125883061, coskunyazgann491@gmail.com
About this study
Official title: Understanding the Experiences and Challenges of People Living With Prostate Cancer
The PROSPEX (PROstate cancer Study of Patient EXperiences) survey is designed to systematically assess the lived experiences, challenges, and unmet needs of individuals diagnosed with prostate cancer. This observational study will collect patient-reported data on psychological, social, and practical aspects of living with prostate cancer, including the impact on quality of life and access to care. The findings aim to inform the development of patient-centered interventions and improve supportive care strategies in future clinical trials and routine practice.
Read the detailed description
Prostate cancer is one of the most common cancers among men worldwide, and its impact extends far beyond medical treatment, affecting many aspects of patients' lives. The PROSPEX (PROstate cancer Study of Patient EXperiences) project is designed to systematically capture the real-world experiences, challenges, and needs of individuals living with prostate cancer across diverse healthcare settings and backgrounds.
Objectives
The primary objectives of the PROSPEX study are:
- To gather comprehensive, patient-reported data on the psychological, social, and practical challenges faced by people with prostate cancer, including the impact on quality of life, relationships, work, and daily living.
- To identify disparities in access to care, supportive services, and information, as well as differences in patient experiences based on disease stage, treatment history, and demographic factors.
- To inform the development of patient-centered care strategies and support services by highlighting unmet needs and areas for improvement in prostate cancer care.
Methods
The PROSPEX survey is an international, anonymous, online questionnaire designed for patients who have been diagnosed with prostate cancer. The survey includes between 70 and 125 questions, depending on each participant's disease stage and treatment history. It covers a wide range of topics, including demographic and clinical information, emotional well-being, social support, financial concerns, experiences with the healthcare system, and the impact of prostate cancer on daily life. The survey is expected to take approximately 30 to 60 minutes to complete. Participation is entirely voluntary, and no sensitive personal data or contact information will be collected or used. The study is investigator-initiated and receives no external funding; the research team declares no conflicts of interest.
Data Analysis Plan
Survey responses will be analyzed using both descriptive and inferential statistical methods. Comparative analyses will be conducted to identify variations in patient experiences across different regions, healthcare systems, and demographic groups. Advanced statistical techniques, such as regression analysis, may be used to explore factors associated with differences in quality of life, access to care, and patient outcomes.
Expected Impact
By systematically documenting the lived experiences of prostate cancer patients worldwide, the PROSPEX project aims to provide valuable insights into the challenges and unmet needs faced by this population. The findings are expected to inform healthcare providers, policymakers, and advocacy groups, guiding the development of more effective, patient-centered care and support services. Ultimately, PROSPEX seeks to improve the quality of life and care outcomes for individuals living with prostate cancer and to contribute to the global understanding of patient experiences in this disease.
- Conditions
- Prostate Cancer
- Being tested
- No Intervention: Observational Cohort
- Keywords
- prostate cancer, survey, patient experience, oncology, health disparities, patient-reported outcomes, cancer care
- Medical subject headings
- Prostatic Neoplasms, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention: Observational CohortOther
No Intervention: Observational Cohort
| Study group | Role | What they receive |
|---|---|---|
| Prostate Cancer Patients | Individuals diagnosed with prostate cancer, regardless of disease stage or treatment status. This group includes patients from diverse backgrounds and healthcare settings who are willing to share their experiences, challenges, and needs related to living with prostate cancer. Receives: Other: No Intervention: Observational Cohort |
What is being measured
The primary outcome is the main question the study is designed to answer.
Characterization of global disparities in patient-reported experiences and quality of life among individuals with prostate cancer
Comparative analyses will be performed using survey data to identify and quantify differences in patient experiences, quality of life, and unmet needs across various regions and healthcare settings. Results will be reported as percentages of respondents, with thorough evaluation of territorial, institutional, and socioeconomic differences. Participants will be categorized according to the World Bank's income classification: low- and lower-middle-income countries, upper-middle-income countries, and high-income countries. Descriptive statistics will be used to compare demographic and clinical characteristics, as well as patient-reported outcomes. For categorical data, Pearson Chi-Square or Fisher's Exact test will be applied; for continuous variables, ANOVA will be used. A p-value of less than 0.05 will be considered statistically significant.
Measured: One month
Secondary outcomes (2)
Identification of factors associated with reduced quality of life and increased psychosocial burden in prostate cancer patients
Multivariate analyses, including regression modeling, will be conducted to explore associations between demographic, clinical, and healthcare system variables and patient-reported outcomes such as emotional well-being, social support, and financial concerns.
Measured: one month
Assessment of disparities in access to supportive care and information among prostate cancer patients
Survey responses will be analyzed to determine differences in access to supportive services, information resources, and patient education across different regions and healthcare systems.
Measured: one month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2025
- Study startAug 2025 (estimated)
- Primary completionDec 2025 (estimated)
- Study completionDec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by Ankara UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 3,000 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Ankara University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yüksel Ürün, Ankara University
- Investigators
- Yüksel Ürün, Study director, Ankara University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07096596
- Sponsor's protocol ID
- ANKARA-UNIVERSITY-YURUN-001
- Acronym
- PROSPEX
- Status last verified
- Jul 2025
- First submitted
- 24 Jul 2025
- Last updated
- 31 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The data that support the findings of this study are available from the study director upon reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Understanding the Experiences and Challenges of People Living With Prostate Cancer
- ClinicalTrials.gov ID
- NCT07096596
- Acronym / sponsor ID
- PROSPEX / ANKARA-UNIVERSITY-YURUN-001
- Conditions
- Prostate Cancer
- Keywords
- prostate cancer, survey, patient experience, oncology, health disparities, patient-reported outcomes, cancer care
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- Ankara UniversityUniversity, hospital or other
- Study start
- Aug 2025 (estimated)
- Primary completion
- Dec 2025 (estimated)
- Study completion
- Dec 2025 (estimated)
- First posted
- 31 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The PROSPEX (PROstate cancer Study of Patient EXperiences) survey is designed to systematically assess the lived experiences, challenges, and unmet needs of individuals diagnosed with prostate cancer. This observational study will collect patient-reported data on psychological, social, and practical aspects of living with prostate cancer, including the impact on quality of life and access to care. The findings aim to inform the development of patient-centered interventions and improve supportive care strategies in future clinical trials and routine practice.
Detailed description
Prostate cancer is one of the most common cancers among men worldwide, and its impact extends far beyond medical treatment, affecting many aspects of patients' lives. The PROSPEX (PROstate cancer Study of Patient EXperiences) project is designed to systematically capture the real-world experiences, challenges, and needs of individuals living with prostate cancer across diverse healthcare settings and backgrounds.
Objectives
The primary objectives of the PROSPEX study are:
- To gather comprehensive, patient-reported data on the psychological, social, and practical challenges faced by people with prostate cancer, including the impact on quality of life, relationships, work, and daily living.
- To identify disparities in access to care, supportive services, and information, as well as differences in patient experiences based on disease stage, treatment history, and demographic factors.
- To inform the development of patient-centered care strategies and support services by highlighting unmet needs and areas for improvement in prostate cancer care.
Methods
The PROSPEX survey is an international, anonymous, online questionnaire designed for patients who have been diagnosed with prostate cancer. The survey includes between 70 and 125 questions, depending on each participant's disease stage and treatment history. It covers a wide range of topics, including demographic and clinical information, emotional well-being, social support, financial concerns, experiences with the healthcare system, and the impact of prostate cancer on daily life. The survey is expected to take approximately 30 to 60 minutes to complete. Participation is entirely voluntary, and no sensitive personal data or contact information will be collected or used. The study is investigator-initiated and receives no external funding; the research team declares no conflicts of interest.
Data Analysis Plan
Survey responses will be analyzed using both descriptive and inferential statistical methods. Comparative analyses will be conducted to identify variations in patient experiences across different regions, healthcare systems, and demographic groups. Advanced statistical techniques, such as regression analysis, may be used to explore factors associated with differences in quality of life, access to care, and patient outcomes.
Expected Impact
By systematically documenting the lived experiences of prostate cancer patients worldwide, the PROSPEX project aims to provide valuable insights into the challenges and unmet needs faced by this population. The findings are expected to inform healthcare providers, policymakers, and advocacy groups, guiding the development of more effective, patient-centered care and support services. Ultimately, PROSPEX seeks to improve the quality of life and care outcomes for individuals living with prostate cancer and to contribute to the global understanding of patient experiences in this disease.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Prostate Cancer Patients | – | Other: No Intervention: Observational CohortIndividuals diagnosed with prostate cancer, regardless of disease stage or treatment status. This group includes patients from diverse backgrounds and healthcare settings who are willing to share their experiences, challenges, and needs related to living with prostate cancer. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of adult individuals (aged 18 and above) who have been diagnosed with prostate cancer, regardless of disease stage or treatment status. Participants will be recruited internationally and will represent a diverse range of backgrounds, healthcare settings, and geographic regions. The study aims to include patients with varying experiences, including those currently undergoing treatment, those in remission, and those living with advanced or recurrent disease. All participants must be able to provide informed consent and complete the online survey.
Key inclusion criteria (2 listed)
- Adults (aged 18 years or older). Diagnosed with prostate cancer at any stage (localized, locally advanced, metastatic, or recurrent).
- Able to understand and provide informed consent for participation. Willing and able to complete the online survey in the available languages. Access to the internet and a device to complete the survey.
Key exclusion criteria (1 listed)
- Individuals who have not been diagnosed with prostate cancer. Individuals under 18 years of age. Inability to provide informed consent. Inability to complete the survey due to cognitive, language, or technical barriers.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention: Observational CohortNo Intervention: Observational Cohort | Other | Prostate Cancer Patients |
Primary outcome
Characterization of global disparities in patient-reported experiences and quality of life among individuals with prostate cancer
Time frame: One month
Comparative analyses will be performed using survey data to identify and quantify differences in patient experiences, quality of life, and unmet needs across various regions and healthcare settings. Results will be reported as percentages of respondents, with thorough evaluation of territorial, institutional, and socioeconomic differences. Participants will be categorized according to the World Bank's income classification: low- and lower-middle-income countries, upper-middle-income countries, and high-income countries. Descriptive statistics will be used to compare demographic and clinical characteristics, as well as patient-reported outcomes. For categorical data, Pearson Chi-Square or Fisher's Exact test will be applied; for continuous variables, ANOVA will be used. A p-value of less than 0.05 will be considered statistically significant.
2 secondary outcomes
Identification of factors associated with reduced quality of life and increased psychosocial burden in prostate cancer patients
Time frame: one month
Assessment of disparities in access to supportive care and information among prostate cancer patients
Time frame: one month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2025.
- Individual participant dataSharing planned: No. The data that support the findings of this study are available from the study director upon reasonable request.
Related trials for Prostate Cancer
Not yet recruiting
Remote Screening and Navigation to Increase Trial Enrollment, INVITE Trial
Bladder Carcinoma, Prostate Carcinoma
RecruitingObservational study
Collection of Blood From Patients With Cancer
Prostate Cancer, Breast Cancer
Active, not recruitingObservational study
Agriculture Health Study
Prostate Cancer, Pesticide Exposures
Active, not recruitingPhase 2
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Prostate Cancer
RecruitingObservational study
Collection of Blood From Patients With Prostate Cancer
Cancer Of Prostate, Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yüksel Ürün study director
Ankara University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prostate Cancer, run by Ankara University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 31 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yüksel Ürün (800-555-5555, yukselurun@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Characterization of global disparities in patient-reported experiences and quality of life among individuals with prostate cancer (time frame: One month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2025; AzTrials last refreshed its copy on 6 Nov 2026.